# The Role of Tomotherapy in Hypofractionated/Dose Escalated Conformal Radiation Treatment for High Risk Prostate Cancer

> **NCT00126802** · PHASE1,PHASE2 · UNKNOWN · sponsor: **AHS Cancer Control Alberta** · enrollment: 60 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **PROCEDURE:** Tomotherapy

## Key facts

- **NCT ID:** NCT00126802
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-04
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2016-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00126802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00126802, "The Role of Tomotherapy in Hypofractionated/Dose Escalated Conformal Radiation Treatment for High Risk Prostate Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00126802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*